Navigation Links
The Asthma Drug Market Will Remain Relatively Flat, Increasing Slightly from $15.3 Billion in 2012 to $16.2 Billion in 2022
Date:12/18/2013

BURLINGTON, Mass., Dec. 18, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the drug market for asthma will remain relatively flat through 2022. Currently, the market is driven by maintenance therapies that successfully treat patients with mild and moderate disease, including market leaders GlaxoSmithKline's long-acting beta2 agonist (LABA)/inhaled corticosteroid (ICS) combination Advair/Seretide/Adoair and Merck's leukotriene inhibitor Singulair (montelukast). These leading agents are already beginning to face generic erosion that will lead their sales to decline.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

The Pharmacor advisory service entitled Asthma finds that the overall market for asthma will remain stable, increasingly slightly from $15.3 billion in 2012 to $16.2 billion in 2022 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. However, the makeup of the biggest sellers in the market will differ in 2022. As the current market leaders undergo generic erosion, including a substantial 67 percent drop in montelukast's sales over the forecast period, asthma sales in later years will be driven by the uptake of GlaxoSmithKline/Theravance's once-daily LABA/ICS combination Breo/Relvar and by four novel anticytokine agents that will serve part of the unmet need in the severe, refractory asthma population.

"Physicians are waiting for more options for their severe, refractory patients beyond oral corticosteroids and the lone biologic approved for asthma, Genentech/Novartis's Xolair, so they are eager to use the new biologics in specific patients," said Decision Resources Analyst Colleen E. Albacker, Ph.D. "Although we anticipate low patient share for these emerging agents, their high price tags will help to offset declining sales due to generic entry of the current market leaders."

The report also finds that Breo/Relvar will perform strongly and act as another key growth driver in the asthma market. Breo/Relvar's once-daily administration will be the first to offer dosing improvement over currently-marketed twice-daily LABA/ICS combinations, and an aggressive marketing campaign will enable it to begin to challenge Advair's dominance in all major markets, although Advair will remain the asthma sales leader.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ViroPharma Announces Upcoming Data Presentations at the 2013 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting
2. Cytos Biotechnology Ltd Announces the Completion of Patient Enrolment in the On-going Phase 2b Study of CYT003 for the Treatment of Allergic Asthma
3. Data for Investigational Tiotropium Show Improved Lung Function and Sustained Bronchodilation in Patients with Moderate Asthma Severity
4. Bronchiale Thermoplastie bietet anhaltende reduktion schwerer Asthmaanfälle über 5 jahre:
5. Bronchiale Tthermoplastie bietet anhaltende reduktion schwerer Asthmaanfälle über 5 jahre:
6. Rigels R343 Did Not Meet Primary Endpoint in Asthma Study
7. iSonea Receives Frost & Sullivan New Product Innovation Leadership Award for its Path-Breaking Mobile Asthma Monitoring App, AsthmaSense
8. Sharp Rees-Stealy Medical Centers Launches Asthmapolis Mobile Asthma Management Program
9. ARRY-502 Meets Primary And Key Secondary Endpoints In Asthma Study
10. Array Biopharma To Report Top-line Results From ARRY-502 Asthma Trial
11. Inspiro Medical Ltd. Completes a Successful First Clinical Trial in Asthmatic Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... of Echenberg Institute, is announcing a new safe and effective at-home VuVa ... other painful pelvic pain conditions such as pelvic floor dysfunction, vulvodynia, vulvar ... ... VuVa ... company, VuVatech LLC, fills a void in the women,s wellness market because ...
(Date:7/10/2017)... , July 10, 2017  US medical equipment ... in 2021, according to Medical Equipment & ... by Freedonia Focus Reports. Continued increases in demand for ... aging of the population and supported by gains in ... equipment and supplies. New product introductions will also drive ...
(Date:7/10/2017)... S.C. , July 10, 2017  BDI ... purchasing and patient support services organization serving specialty ... today the launch of four significant, value-added member ... market insights, better manage reimbursement and improve access ... and factor therapies. ...
Breaking Medicine Technology:
(Date:7/27/2017)... ... July 28, 2017 , ... ... upcoming episode of the award-winning television series, American Famer, scheduled to broadcast fourth ... , Syngenta is dedicated to helping humanity face its toughest challenge: how to ...
(Date:7/27/2017)... ... July 27, 2017 , ... MEDsys Software Solutions, the ... Care Organizations and Home Care Agencies, has been awarded CIO Applications Magazine’s Top ... solutions to over 1,000 agencies and multiple State Medicaid and Managed Care Programs. ...
(Date:7/27/2017)... ... July 27, 2017 , ... GAFFEY Healthcare, a leading provider ... Clinkscales to Vice President of Revenue Cycle Business Services and Suzanne Dusak to ... chief executive officer (CEO). , Elrene has been with company since Oct 2014 ...
(Date:7/27/2017)... ... 27, 2017 , ... Healthy eating isn’t always easy. Currently, more than 80 percent of Americans ... Americans overeat refined grains and sugar. This trend may help explain why the obesity rate ... are obese. , As a culture, we seem to have food on the brain more. ...
(Date:7/27/2017)... ... July 27, 2017 , ... ... compete to form startup companies around 117 breakthrough inventions from 55 institutions, including ... Institute, and National Institute of Biomedical Imaging and Bioengineering), the United States Army, ...
Breaking Medicine News(10 mins):